Huntingtin Mutant Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurons expressing mutant huntingtin protein (mHTT) characterized by expanded polyglutamine (PolyQ) repeats, leading to progressive neurodegeneration in Huntington's disease.
| Property | Value |
|---|---|
| Category | Disease-Specific Neurons |
| Location | Striatum, cortex, hippocampus, thalamus |
| Cell Types | Medium spiny neurons, cortical pyramidal neurons, hippocampal neurons |
| Primary Neurotransmitter | GABA (MSNs), Glutamate (pyramidal) |
| Key Markers | mHTT, PolyQ expansion, mutant huntingtin aggregates |
Huntingtin mutant neurons are neurons affected by mutations in the HTT gene that cause Huntington's disease (HD), an autosomal dominant neurodegenerative disorder. The mutation involves an expanded CAG trinucleotide repeat encoding a polyglutamine (PolyQ) tract in the huntingtin protein. Neurons expressing mutant huntingtin (mHTT) undergo progressive dysfunction and cell death, leading to the characteristic motor, cognitive, and psychiatric symptoms of HD.
The HTT gene (also called IT15 - "interesting transcript 15") encodes the huntingtin protein, which is essential for normal neuronal function. In Huntington's disease, a CAG trinucleotide repeat expansion in the first exon of HTT results in an abnormally long polyglutamine tract in the huntingtin protein:
The age of onset correlates inversely with repeat length - longer repeats lead to earlier onset and more severe disease 1.
The mutated huntingtin protein acquires toxic gain-of-function properties while also losing some normal functions:
The most severely affected neurons in HD are the medium spiny neurons (MSNs) of the striatum. These GABAergic neurons project to the globus pallidus and substantia nigra pars reticulata, forming the indirect and direct pathways of the basal ganglia motor circuit 2.
Characteristics of affected MSNs:
Cortical degeneration, particularly in layers 3, 5, and 6, occurs alongside striatal pathology. These glutamatergic neurons show:
Memory deficits in HD involve hippocampal dysfunction. CA1 pyramidal neurons and interneurons show:
mHTT disrupts normal gene expression through multiple mechanisms 4:
Key dysregulated genes include:
mHTT impairs mitochondrial function at multiple levels 5:
Neuronal processes require efficient transport of organelles, proteins, and signaling molecules. mHTT disrupts:
Striatal neurons are particularly vulnerable to excitotoxic damage:
mHTT forms various aggregated species:
The relationship between aggregation and toxicity remains complex - some evidence suggests aggregates may be protective by sequestering toxic soluble species.
mHTT activates both intrinsic and extrinsic apoptotic pathways:
Degeneration of striatal MSNs leads to:
Cortical and hippocampal involvement causes:
CSF Biomarkers:
Imaging Biomarkers:
Gene Silencing Therapies:
Small Molecule Therapies:
Cell-Based Therapies:
Symptomatic Treatments:
The study of Huntingtin Mutant Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1 The Huntington's Disease Collaborative Research Project. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983. PMID:7502064
2 Graybiel AM. The basal ganglia. Curr Biol. 2000;10(14):R509-511. PMID:14519201
3 Raymond LA, et al. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 2011;198:252-273. PMID:19879261
4 Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol. 2007;83(3):176-191. PMID:17630856
5 Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443(7113):787-795. PMID:19028584
6 Gunawardena S, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40(1):25-40. PMID:15777740
7 Tabrizi SJ, et al. Huntington disease: Natural history, biomarkers and future prospects. Nat Rev Neurol. 2022;18(2):99-112. PMID:32453818
8 Kordasiewicz HB, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031-1044. PMID:31242562